NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

RecruitingN/A

Sponsor: Innopeutics Corporation

Conditions: Parkinson Disease, Parkinson's Disease

Countries: South Korea

The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.

Eligibility overview

Sex: ALL

Age: 50 Years to 80 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria

* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.
* Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.

Exclusion Criteria

* Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.
* Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.

Locations (1)

Seoul, South Korea